Risk assessment of hepatocellular carcinoma in chronic liver disease by using liver stiffness measurement

Risk assessment of hepatocellular carcinoma in chronic liver disease by using liver stiffness measurement - Risk assessment of hepatocellular carcinoma in chronic liver disease by using liver stiffness measurement

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029437

Enrollment

2000

Registered

2017-10-06

Start date

2017-09-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic liver disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who are 20 years of age or older at the time of obtaining informed consent 2. Patients who are informed and have provided written informed consent to participate in the study prior to study initiation 3. Patients with chronic liver disease who do not meet any of the following exclusion criteria

Exclusion criteria

Exclusion criteria: 1. Patients with difficult controlled cardiac disease 2. Patients by whom doctor in charge has determined to be inappropriate as a subject 3. Patients by whom principal investigator has determined to be inappropriate as a subject

Design outcomes

Primary

Measure	Time frame
Relevance between liver stiffness and development of HCC	—

Secondary

Measure	Time frame
1) Relevance between liver stiffness and fibrosis marker 2) Relevance between liver stiffness and tumor marker 3) Relevance between liver stiffness and blood biochemical examination 4) Relevance between liver stiffness and glucose-metabolic disorders 5) Relevance between liver stiffness and lipid- metabolic disorders	—

Countries

Japan

Contacts

Public ContactGoki Suda

Hokkaido University Hospital Department of Gastroenterology and Hepatology

gsudgast@pop.med.hokudai.ac.jp011-716-1161

Outcome results